Related Experiment Video
Updated: Aug 9, 2026
11:37
QTL Mapping and CRISPR/Cas9 Editing to Identify a Drug Resistance Gene in Toxoplasma gondii
Published on: June 22, 2017
Summary
Genetic factors influencing tolbutamide metabolism may explain adverse effects observed in the University Group Diabetes Program (UGDP) study. Slow metabolizers, a significant population segment, might accumulate toxic drug levels, potentially impacting study outcomes.
Area of Science:
- Pharmacogenetics
- Clinical Trials
- Diabetes Mellitus Management
Background:
- The University Group Diabetes Program (UGDP) study reported controversial findings regarding tolbutamide efficacy and safety.
- Genetic variability in drug metabolism, specifically tolbutamide, was not well understood prior to the UGDP study.
- Tolbutamide was administered at a fixed dosage (1,500 mg/day) to all participants in the UGDP treatment group.
Purpose of the Study:
- To investigate the potential role of pharmacogenetics in the adverse effects observed in the UGDP study.
- To test the hypothesis that genetic variations in tolbutamide metabolism could have influenced UGDP study outcomes.
- To explore the link between genetic predisposition to slow tolbutamide inactivation and potential toxicity.
Main Methods:
- Analysis of existing data and literature on tolbutamide pharmacogenetics.
- Review of findings from population, twin, and family studies on drug metabolism.
- Hypothetical modeling of tolbutamide blood levels based on genetic inactivation rates.
Main Results:
- Recent studies indicate that tolbutamide metabolism is under monogenic control.
- Approximately one-fourth of the population are identified as slow inactivators of tolbutamide.
- This genetic variation suggests a potential mechanism for differential drug exposure and toxicity.
Conclusions:
- Genetic factors controlling tolbutamide metabolism likely influenced the UGDP study results.
- Slow inactivators may experience higher, potentially toxic, blood levels of tolbutamide.
- Pharmacogenetic considerations are crucial for interpreting historical clinical trial data and informing future drug studies.
Related Concept Videos
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...